Please try another search
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Pratik Shah | 54 | - | Chairman of the Board |
Phillip Lieberman | - | - | Member of Scientific Advisory Board |
Michael Kelly | 58 | - | Director |
Anne K. Ellis | - | 2021 | Member of Scientific Advisory Board |
Thomas B. Casale | - | - | Member of Scientific Advisory Board |
Peter Kolchinsky | 47 | 2021 | Director |
Brenton L. Saunders | 54 | 2021 | Director |
Rajeev Dadoo | 53 | 2021 | Director |
Michael Kaliner | - | - | Member of Scientific Advisory Board |
Jonathan M. Spergel | - | 2023 | Member of the Scientific Advisory Board |
David I. Bernstein | - | 2023 | Member of Scientific Advisory Board |
David M. Fleischer | - | 2023 | Member of Scientific Advisory Board |
Richard F. Lockey | - | - | Member of Scientific Advisory Board |
Carlos A. Camarago | - | 2023 | Member of Scientific Advisory Board |
Laura K. Shawver | 66 | 2022 | Director |
Phillip M. Schneider | 68 | - | Director |
Motohiro Ebisawa | - | - | Member of Scientific Advisory Board |
Saqib Islam | 54 | 2022 | Director |
Peter A. Thompson | 64 | 2022 | Director |
Richard Lowenthal | 58 | 2022 | Founder, President, CEO & Director |
John Oppenheimer | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review